Announced

ADQ to invest $75m in Biocon Biologics.

Synopsis

ADQ, a holding company, agreed to invest $75m in Biocon Biologics, a biopharmaceutical company, valuing the company at $4.17bn. “This investment is an endorsement of the value that the Biocon Biologics business has built as a fully integrated pure-play biosimilars company and will enable us to expand our capabilities further. We are committed to pursue our affordable innovation model to generate savings for the healthcare systems worldwide,” Kiran Mazumdar-Shaw, Biocon Executive Chairperson.

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Sort

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US